News for AC Immune SA (ACIU)

On May 1, 2025, analyst Andrew Fein from HC Wainwright & Co. maintained a "Buy" rating on AC Immune (ACIU). The stock rating remains unchanged from its prior "B

H.C. Wainwright has adjusted its price target for AC Immune (ACIU), reducing it from $16 to $12 while maintaining a Buy rating for the company. The decision fol

AC Immune (ACIU) reported first-quarter revenue of $990,000, significantly exceeding analysts' expectations of $323,670. The company's portfolio, focused on act

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precis

**media[583551]**

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PDâ„¢ 2025 AC Immune to host symposium highlighting the compa

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $

AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

**media[556679]**

AC Immune to Participate in Upcoming Investor Conferences Lausanne, Switzerland, March 4, 2025 ”“ AC Immune SA ( ACIU), a clinical-stage biopharmaceutical com

Explore AC Immune's innovative Alzheimer's and Parkinson's therapies, key pharma collaborations, and financial outlook. Learn more on ACIU stock here.

The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

AC Immune (ACIU) stock shot up 20% Thursday after the company reported positive data from a Phase 2 study of its drug ACI-7104.056 in the treatment of early Parkinson’s disease.

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling by more than 150 points on Thursday. The Dow traded down 0.38% to 43,790.8...

U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Thursday. Shares of Hillenbrand, Inc. HI rose sharply in today's session follo...

**media[464664]**

**media[456652]**

AC Immune SA (ACIU) is set to release its Q3 2024 earnings on Oct 24, 2024. The consensus estimate for Q3 2024 revenue is $1.71 million, and the earnings are ex

Shares of Granite Point Mortgage Trust Inc. GPMT rose sharply in today's pre-market trading after the company announced a third-quarter common and preferred sto...